Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
alloRESIST
NCT04248192Phase 1Active, not recruiting
- Sponsor
- Catherine Bollard
- Start
- May 2020
- Primary completion
- Nov 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HST-NEETs in human immunodeficiency virus infection (HIV), sponsored by Catherine Bollard. Primary endpoint: Any >= Grade 3 Adverse Events at 45 days. Started May 2020; status: active, not recruiting.
02
Drugs
HST-NEETs
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04248192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248192.